These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18611977)

  • 21. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
    Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
    Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
    Feenstra J; van Aken MO; de Herder WW; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2006 Jun; 154(6):805-6. PubMed ID: 16728538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
    Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
    J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
    Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
    van der Lely AJ; Bernabeu I; Cap J; Caron P; Colao A; Marek J; Neggers S; Birman P
    Eur J Endocrinol; 2011 Mar; 164(3):325-33. PubMed ID: 21148630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
    Trainer PJ
    J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegvisomant-induced lipohypertrophy: report of a case with histopathology.
    Marazuela M; Daudén E; Ocón E; Moure D; Nattero L
    Ann Intern Med; 2007 Nov; 147(10):741-3. PubMed ID: 18025453
    [No Abstract]   [Full Text] [Related]  

  • 34. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
    Neggers SJ; van Aken MO; de Herder WW; Feelders RA; Janssen JA; Badia X; Webb SM; van der Lely AJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3853-9. PubMed ID: 18647806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.
    Morin E; Berthelet F; Weisnagel J; Bidlingmaier M; Serri O
    Pituitary; 2012 Mar; 15(1):97-100. PubMed ID: 20407837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly.
    Madsen M; Fisker S; Feldt-Rasmussen U; Andreassen M; Kristensen LØ; Ørskov H; Jørgensen JO
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):92-100. PubMed ID: 23650996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
    Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
    Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
    Parkinson C; Burman P; Messig M; Trainer PJ
    J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
    Jimenez C; Burman P; Abs R; Clemmons DR; Drake WM; Hutson KR; Messig M; Thorner MO; Trainer PJ; Gagel RF
    Eur J Endocrinol; 2008 Nov; 159(5):517-23. PubMed ID: 18708436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
    Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
    Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.